The acquisition includes a vaccine and biologics manufacturing facility and other support buildings in Jevany, Czech Republic, together with the company’s existing employees and all related and required infrastructure. The value of the transaction is approximately USD 167 million.

The newly acquired facility is expected to provide an annual production capacity of over 1 billion doses of antigen starting in 2021 for NVX‑CoV2373—Novavax’s COVID-19 vaccine candidate. The acquisition of Praha Vaccines is supported by Novavax’s funding arrangement with the Coalition for Epidemic Preparedness Innovations (CEPI), which enables Novavax to dramatically expand its manufacturing capacity.

The Kinstellar team was led by Jan Juroška, Partner, and included Tomáš Čihula, Partner, Associates Martina Mazůrková, Martin Holub, and Junior Associates Matěj Večeřa, Štěpánka Havlíková, Alice Radvanovská, Veronika Rožnovská and Sabina Skoumalová.